

**Amendments to the Specification:**

Please replace the first full paragraph on page 8 of the SUBSTITUTE SPECIFICATION filed on October 29, 2008 with the following amended paragraph:

Fig. 1 is a graph showing the changes of intraocular pressure with time in respective administration groups. The intraocular pressure is expressed as a change from an initial intraocular pressure. □ represents a Compound A ((R)-(+) -N-(1H-pyrrolo[2,3-b] [[pyridine]] pyridin-4-yl)-4-(1-aminoethyl)-benzamide dihydrochloride) and isopropyl unoprostone combination administration group, ■ represents a single administration group of Compound A, Δ represents a single administration group of isopropyl unoprostone, and ○ represents a control group.

Please replace the paragraph bridging pages 8 and 9 of the SUBSTITUTE SPECIFICATION filed on October 29, 2008 with the following amended paragraph:

Fig. 3 is a graph showing the changes of intraocular pressure with time in respective administration groups. The intraocular pressure is expressed as a change from an initial intraocular pressure. □ represents a Compound A ((R)-(+)-N-(1H-pyrrolo[2,3-b] [[pyridine]] pyridin-4-yl)-4-(1-aminoethyl)-benzamide dihydrochloride) and a latanoprost combination administration group, ■ represents a single administration group of Compound A, Δ represents a single administration group of latanoprost, and ○ represents a control group.